JP2009537526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537526A5 JP2009537526A5 JP2009510991A JP2009510991A JP2009537526A5 JP 2009537526 A5 JP2009537526 A5 JP 2009537526A5 JP 2009510991 A JP2009510991 A JP 2009510991A JP 2009510991 A JP2009510991 A JP 2009510991A JP 2009537526 A5 JP2009537526 A5 JP 2009537526A5
- Authority
- JP
- Japan
- Prior art keywords
- cationic
- antibody
- complex
- immunoliposome
- small molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002091 cationic group Chemical group 0.000 claims 43
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 18
- 239000002502 liposome Substances 0.000 claims 17
- 150000003384 small molecules Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 235000012000 cholesterol Nutrition 0.000 claims 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 cationic lipid Chemical class 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 229960005073 erlotinib hydrochloride Drugs 0.000 claims 3
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960003685 imatinib mesylate Drugs 0.000 claims 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 3
- 229960002812 sunitinib malate Drugs 0.000 claims 3
- HPGLFJZJIHFMIT-UHFFFAOYSA-N 2-[4-(2-methylphenyl)phenyl]-6-nitro-2,3-dihydro-1h-quinazolin-4-one Chemical compound CC1=CC=CC=C1C1=CC=C(C2NC3=CC=C(C=C3C(=O)N2)[N+]([O-])=O)C=C1 HPGLFJZJIHFMIT-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 241000255925 Diptera Species 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 241001061127 Thione Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80016306P | 2006-05-15 | 2006-05-15 | |
| US84435206P | 2006-09-14 | 2006-09-14 | |
| PCT/US2007/011407 WO2007142781A1 (en) | 2006-05-15 | 2007-05-11 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537526A JP2009537526A (ja) | 2009-10-29 |
| JP2009537526A5 true JP2009537526A5 (OSRAM) | 2010-07-01 |
Family
ID=38801787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510991A Pending JP2009537526A (ja) | 2006-05-15 | 2007-05-11 | 治療もしくは診断剤の全身投与のための抗体もしくは抗体断片標的化免疫リポソームの製造およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9034330B2 (OSRAM) |
| EP (1) | EP2023897A4 (OSRAM) |
| JP (1) | JP2009537526A (OSRAM) |
| KR (2) | KR20140135267A (OSRAM) |
| AU (1) | AU2007257357B2 (OSRAM) |
| CA (1) | CA2652222A1 (OSRAM) |
| IL (1) | IL195216A (OSRAM) |
| MX (1) | MX2008014362A (OSRAM) |
| WO (1) | WO2007142781A1 (OSRAM) |
| ZA (1) | ZA200809725B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034330B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| CN103655475B (zh) | 2012-09-19 | 2020-04-28 | 乔治敦大学 | 靶向的脂质体 |
| US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| KR20150131263A (ko) | 2013-03-14 | 2015-11-24 | 조지타운 유니버시티 | 신경 작용제에 대한 노출을 위한 치료 |
| US11136609B2 (en) | 2015-11-09 | 2021-10-05 | National University Corporation Kyoto Institute Of Technology | Separating agent for human serum-derived IgG polyclonal antibodies, and method for separating human serum-derived IgG polyclonal antibodies using same |
| US12274784B2 (en) * | 2018-10-12 | 2025-04-15 | Synergene Therapeutics, Inc. | Methods for reducing side effects of immunotherapy |
| US20230302154A1 (en) * | 2020-08-19 | 2023-09-28 | The Board Of Regents Of The University Of Texas System | Nanodrugs for targeted drug delivery and use thereof |
| WO2022226513A1 (en) * | 2021-04-21 | 2022-10-27 | University Of Florida Research Foundation, Inc. | Enzymatically-cleavable glycidyl methacrylate hyaluronic acid |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4429008B1 (en) | 1981-12-10 | 1995-05-16 | Univ California | Thiol reactive liposomes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| AU642980B2 (en) | 1990-03-21 | 1993-11-04 | Quest International B.V. | Ultilization of enzymes |
| US6099842A (en) | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
| US5705655A (en) | 1992-12-17 | 1998-01-06 | Megabios Corporation | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses |
| WO1995035301A1 (en) | 1994-06-22 | 1995-12-28 | Megabios Corporation | Cationic amphiphiles |
| US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
| JPH09110722A (ja) * | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
| EP0904100B1 (en) | 1996-02-09 | 2006-07-26 | Pi-Wan Cheng | Cationic lipid and receptor ligand-facilitated delivery of biologically active molecules |
| PT956001E (pt) | 1996-11-12 | 2012-12-06 | Univ California | Preparação de formulações estáveis de complexos do tipo lípido-ácido nucleico para uma entrega eficiente in vivo |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| AU759164C (en) | 1997-11-19 | 2007-03-29 | Georgetown University | Targeted liposome gene delivery |
| US6794128B2 (en) | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| WO1999059643A2 (en) | 1998-05-20 | 1999-11-25 | Sdg, Inc. | Liposomal delivery complex |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| DE69929074T2 (de) | 1998-09-11 | 2006-08-10 | Thomas Jefferson University | Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen |
| US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| EP1811036B8 (en) | 1999-02-22 | 2011-09-21 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| US9034330B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| CN1448183A (zh) * | 2002-04-04 | 2003-10-15 | 深圳市生尔易实业发展有限责任公司 | 一种肿瘤特异性靶向给药系统及其在制备治疗肿瘤药物中的应用 |
| CA2528411C (en) * | 2003-06-04 | 2012-09-04 | Georgetown University | Method for improving stability and shelf-life of liposome complexes |
| JP2005306865A (ja) * | 2004-03-25 | 2005-11-04 | Japan Science & Technology Agency | ホウ酸基含有シス−スチルベン化合物及びその製造方法、並びに、ホウ酸基含有トランス−スチルベン化合物及びその製造方法 |
| JP4593961B2 (ja) | 2004-04-20 | 2010-12-08 | Ｔｈｋ株式会社 | 直動案内用広速度域グリース組成物及びこれを用いた直動案内装置 |
| EP1750706B1 (en) * | 2004-06-01 | 2016-10-05 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
-
2007
- 2007-05-11 US US11/798,296 patent/US9034330B2/en not_active Expired - Fee Related
- 2007-05-11 KR KR1020147031229A patent/KR20140135267A/ko not_active Ceased
- 2007-05-11 EP EP07809069A patent/EP2023897A4/en not_active Withdrawn
- 2007-05-11 CA CA002652222A patent/CA2652222A1/en not_active Abandoned
- 2007-05-11 KR KR1020087030321A patent/KR101573928B1/ko not_active Expired - Fee Related
- 2007-05-11 JP JP2009510991A patent/JP2009537526A/ja active Pending
- 2007-05-11 WO PCT/US2007/011407 patent/WO2007142781A1/en not_active Ceased
- 2007-05-11 MX MX2008014362A patent/MX2008014362A/es active IP Right Grant
- 2007-05-11 AU AU2007257357A patent/AU2007257357B2/en not_active Ceased
-
2008
- 2008-11-11 IL IL195216A patent/IL195216A/en active IP Right Grant
- 2008-11-14 ZA ZA2008/09725A patent/ZA200809725B/en unknown
-
2015
- 2015-04-24 US US14/695,841 patent/US9480750B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537526A5 (OSRAM) | ||
| Pillai | Nanotechnology toward treating cancer: A comprehensive review | |
| RU2007137492A (ru) | Новые композиции липосом | |
| de Araújo Lopes et al. | Liposomes as carriers of anticancer drugs | |
| Yang et al. | Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells | |
| CN104582732A (zh) | 治疗癌症的组合物及其制造方法 | |
| WO2013173693A1 (en) | Nanoparticles with enhanced entry into cancer cells | |
| Liu et al. | Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent | |
| JP2008538105A5 (OSRAM) | ||
| Lila et al. | Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor | |
| Huang et al. | Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs | |
| Orthmann et al. | Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes | |
| US10617672B2 (en) | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | |
| Biagiotti et al. | Combined therapies with nanostructured carbon materials: there is room still available at the bottom | |
| Sempkowski et al. | Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs, therapeutic efficacy | |
| CN108883068B (zh) | 乳癌治疗 | |
| JP2009512712A5 (OSRAM) | ||
| CN108350036A (zh) | 用于改善疏水性药物功效的制剂 | |
| Stanczyk et al. | Dendrimers in therapy for breast and colorectal cancer | |
| JP7204744B2 (ja) | ｃ（ＲＧＤ－ＡＣＰ－Ｋ）修飾血中滞留型リポソーム | |
| CN111001011B (zh) | 一种低分子量肝素修饰的骨靶向脂质体及其制备方法 | |
| WO2021072407A1 (en) | Delivery system complexes comprising a precipitate of an active agent and methods of use | |
| EP4013444A1 (en) | Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer | |
| JP2022517352A (ja) | マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法 | |
| Bohl Kullberg | Tumor Cell Targeting of Stabilized Liposome Conjugates: Experimental studies using boronated DNA-binding agents |